Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12647223 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL12522917 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL1293449 | 0.80 | GSK3B (0.41) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL4642665 | 0.79 | ALDH1A1 (0.69) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL27347353 | 0.79 | ALDH1A1 (0.74) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL354679 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5358823 | 0.77 | ALDH1A1 (0.71) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL29623278 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL1459295 | 0.76 | MGAM (0.61) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28182944 | 0.76 | ALDH1A1 (0.54) | ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012168733-A1 | SUBSTITUTED 8 - AMINO - IMIDAZO [1, 2-A] PYRAZINES AS ANTIBACTERIAL AGENTS | UCL BUSINESS PLC (GB) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168733-A1 | SUBSTITUTED 8 - AMINO - IMIDAZO [1, 2-A] PYRAZINES AS ANTIBACTERIAL AGENTS | UCL BUSINESS PLC (GB) | 2012-12-13 | — | — | WO | disclosed |
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | disclosed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1343780-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-6610848-B1 | Platinum 1,2-enedithiolates; L2Pt(S2C2(2-pyridine)(H) wherein L2 is bis(diphenyldiphoshino)methane (dppm), 1,2-bis(diphenyldiphosphino)ethane (dppe) or 1,3-bis(diphenyldiphosphino)propane (dppp) | LUMET LLC | 2003-08-26 | — | — | US | disclosed |
| WO-2002050061-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | MYD88, THPO, PIGO | ALDH1A1 1678/4885HPGD 122/4885ALOX15 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.